BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

GV leads $80M series B for COVID antibody play AdagioAdagio Therapeutics Inc. raised $80 million in a series B round led by GV, with backing from existing investors Polaris Partners, Mithril Capital, Fidelity Management &...
BioCentury | May 29, 2019
Company News

May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
BioCentury | Jun 27, 2016
Product Development

Fishing upstream

Anti-inflammatory biologics have transformed the treatment of autoimmune diseases, but Johnson & Johnson's Janssen Research & Development LLC unit wants to intercept the processes that lead to inflammation in the first place. As early as...
BioCentury | Oct 5, 2015
Tools & Techniques

J&J intercepts Nextera

Johnson & Johnson's option deal with Nextera A/S could add another tool to the pharma's growing arsenal of T cell-based technologies for intercepting immunological diseases before they start. On Sept. 21, Nextera granted J&J's Janssen...
BioCentury | Feb 26, 2015
Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
BioCentury | Feb 5, 2007
Strategy

Sticking to core values

Novo Nordisk A/S is dropping small molecules in order to focus on turning its mature biologics franchise into an engine for growth and diversification. By returning to its recombinant protein roots, the company hopes to...
BioCentury | Sep 27, 2004
Tools & Techniques

Building on safe ground

Since the advent of technologies to generate antibodies in the lab in 1975, a great many companies have been founded on the premise that these platforms could easily be used to crank out treatments for...
BioCentury | May 31, 2004
Company News

Cerep SA, Molecular Engines Laboratories SA deal

...SA id it plans to acquire target identification company Molecular Engines for 400,000 shares, which values Molecular Engines...
...do not accept the increase in share capital, the acquisition will be made in cash. Molecular Engines...
...models and identified genes related to acute myeloid leukemia (AML). Cerep SA (NM:Cerep), Paris, France Molecular Engines...
BioCentury | Jan 12, 2004
Financial News

Burrill closes $211M fund

Merchant bank Burrill & Co. closed its Burrill Life Sciences Capital Fund at $211 million. The fund plans to make $5-$15 million investments in series A, B or C rounds of therapeutic, diagnostic, device and...
Items per page:
1 - 10 of 19
BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

GV leads $80M series B for COVID antibody play AdagioAdagio Therapeutics Inc. raised $80 million in a series B round led by GV, with backing from existing investors Polaris Partners, Mithril Capital, Fidelity Management &...
BioCentury | May 29, 2019
Company News

May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
BioCentury | Jun 27, 2016
Product Development

Fishing upstream

Anti-inflammatory biologics have transformed the treatment of autoimmune diseases, but Johnson & Johnson's Janssen Research & Development LLC unit wants to intercept the processes that lead to inflammation in the first place. As early as...
BioCentury | Oct 5, 2015
Tools & Techniques

J&J intercepts Nextera

Johnson & Johnson's option deal with Nextera A/S could add another tool to the pharma's growing arsenal of T cell-based technologies for intercepting immunological diseases before they start. On Sept. 21, Nextera granted J&J's Janssen...
BioCentury | Feb 26, 2015
Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
BioCentury | Feb 5, 2007
Strategy

Sticking to core values

Novo Nordisk A/S is dropping small molecules in order to focus on turning its mature biologics franchise into an engine for growth and diversification. By returning to its recombinant protein roots, the company hopes to...
BioCentury | Sep 27, 2004
Tools & Techniques

Building on safe ground

Since the advent of technologies to generate antibodies in the lab in 1975, a great many companies have been founded on the premise that these platforms could easily be used to crank out treatments for...
BioCentury | May 31, 2004
Company News

Cerep SA, Molecular Engines Laboratories SA deal

...SA id it plans to acquire target identification company Molecular Engines for 400,000 shares, which values Molecular Engines...
...do not accept the increase in share capital, the acquisition will be made in cash. Molecular Engines...
...models and identified genes related to acute myeloid leukemia (AML). Cerep SA (NM:Cerep), Paris, France Molecular Engines...
BioCentury | Jan 12, 2004
Financial News

Burrill closes $211M fund

Merchant bank Burrill & Co. closed its Burrill Life Sciences Capital Fund at $211 million. The fund plans to make $5-$15 million investments in series A, B or C rounds of therapeutic, diagnostic, device and...
Items per page:
1 - 10 of 19